# Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients

> **NCT05382078** · — · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 188 (estimated)

## Conditions studied

- Sepsis Syndrome
- MODS
- AKI
- Hemorrhage
- Trauma
- Thrombus

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05382078
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-31
- **Primary completion:** 2023-05-04
- **Final completion:** 2024-05-03
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2022-05-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382078, "Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05382078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*